打开主菜单

ZMapp是一种用来产生对埃博拉病毒免疫反应的药物,该药物是三个人源化抗体的血清混合物。[1][2][3] 2014年7月31日,该药物在病人上开始了第一次试验。两位感染了埃博拉病毒的美国人接受了治疗。一位患者在施药后都有了好转的迹象、另一位因有併發症而宣告死亡。[4][5] 2014年8月22日院方召開記者會[6]表示1人已完全康復,不過院方指他們不清楚Zmapp是否有效,也不確定患者是因藥物康復或是自行康復,也不清楚2位病患接受的實驗性治療,是否會出現長期的副作用,但感染伊波拉康復的病人,不會再復發也不具傳染性,並指出營養比較好的病患通常有比較高的存活率。另一名在賴比瑞亞感染伊波拉病毒的75歲西班牙神父也使用ZMapp,但也宣告不治。

ZMapp是由Mapp生物制药公司开发的,[7]是Mapp生物制药(圣迭戈)、LeafBio(Mapp生物制药的商业部门)、[8]Defyrus公司(多伦多)、美国政府以及加拿大公共卫生署联合的成果。[1]该抗体出自十几年前由美国军方资助的研究项目。[9] 美国国防威胁降低局已经宣布,基于“良好的前景”,将追加对Mapp生物制药的投资。[10]

参考文献编辑

  1. ^ 1.0 1.1 ZMapp Information Sheet (PDF). Mapp Biopharmaceutical. (原始内容 (PDF)存档于2014-08-12). 
  2. ^ Larry Zeitlin, James Pettitt, Corinne Scully, Natasha Bohorova, Do Kim, Michael Pauly, Andrew Hiatt, Long Ngo, Herta Steinkellner, Kevin J. Whaley, and Gene G. Olinger. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. PNAS. 2011. doi:10.1073/pnas.1108360108. 
  3. ^ Gene Garrard Olinger Jr, James Pettitt, Do Kim, Cara Working, Ognian Bohorov, Barry Bratcher, Ernie Hiatt, Steven D. Hume, Ashley K. Johnson, Josh Morton, Michael Pauly, Kevin J. Whaley, Calli M. Lear, Julia E. Biggins, Corinne Scully, Lisa Hensley, and Larry Zeitlin. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. PNAS. 2012. doi:10.1073/pnas.1213709109. 
  4. ^ Dr. Sanjay Gupta and Danielle Dellorto. Experimental drug likely saved Ebola patients. CNN. August 4, 2014. 
  5. ^ "Mystery Ebola virus serum manufactured by San Diego firm". Los Angeles Times. August 4, 2014.
  6. ^ "伊波拉剋星或面世美染病醫生康復出院" 巴士的報 2014年08月22日
  7. ^ "Mystery Ebola virus serum manufactured by San Diego firm". Los Angeles Times. August 4, 2014.
  8. ^ LeafBio. [August 12, 2014]. 
  9. ^ Robert Langreth, Caroline Chen, James Nash and John Lauerman. Ebola Drug Made From Tobacco Plant Saves U.S. Aid Workers. BusinessWeek. August 4, 2014. 
  10. ^ The U.S. Is Sitting on Promising Ebola Vaccines. NewsWeek. August 4, 2014.